ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020
Endothelial-derived plasma exosome proteins in Alzheimer's disease angiopathy.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Oral Microbial Extracellular Vesicles as Novel Mediators of Alzheimer's Pathogenesis: A Critical Review of the Periodontal-Brain Axis.Neurotoxicity research · 2026Review
- Exosomes as Therapeutic and Diagnostic Tools: Advances, Challenges, and Future Directions.Cell biochemistry and biophysics · 2025Review
- Multiomics Profiling of Extracellular Vesicles Supports Their Involvement in Endothelial Senescence-Associated Vascular Dysfunction.Journal of extracellular biology · 2025Article
- WMH Contributions to Cognitive Impairment: Rationale and Design of the Diverse VCID Study.Stroke · 2025Review
- Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.Translational neurodegeneration · 2024Review
- Emergence of Extracellular Vesicles as "Liquid Biopsy" for Neurological Disorders: Boom or Bust.Pharmacological reviews · 2024Review
- Key developments and hotspots of exosomes in Alzheimer's disease: a bibliometric study spanning 2003 to 2023.Frontiers in aging neuroscience · 2024Article
- Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities.Biomolecules · 2023Review
- Cooked pork-derived exosome nanovesicles mediate metabolic disorder-microRNA could be the culprit.Journal of nanobiotechnology · 2023Article
- Plasma derived extracellular vesicle biomarkers of microglia activation in an experimental stroke model.Journal of neuroinflammation · 2023Article
- Extracellular vesicles in the study of Alzheimer's and Parkinson's diseases: Methodologies applied from cells to biofluids.Journal of neurochemistry · 2022Review
- Article
- Review on the roles of specific cell-derived exosomes in Alzheimer's disease.Frontiers in neuroscience · 2022Review
- Transcriptomic Profile of Blood-Brain Barrier Remodeling in Cerebral Amyloid Angiopathy.Frontiers in cellular neuroscience · 2022Article
- Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- Biomarkers involved in the pathogenesis of cerebral small-vessel disease.Frontiers in neurology · 2022Review
- A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.Mechanisms of ageing and development · 2021Review
- Isolation and characterization of extracellular vesicles in saliva of children with asthma.Extracellular vesicles and circulating nucleic acids · 2021Article
- Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study.Neurobiology of aging · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Small cerebral vascular disease (SCeVD) demonstrated by white matter hyperintensity (WMH) on MRI contributes to the development of dementia in Alzheimer's disease (AD), but it has not been possible to correlate onset, severity, or protein components of SCeVD with characteristics of WMH in living patients. Plasma endothelial-derived exosomes (EDEs) were enriched by two-step immunoabsorption from four groups of participants with no clinical evidence of cerebrovascular disease: cognitively normal (CN) without WMH (CN without SCeVD, n = 20), CN with SCeVD (n = 22), preclinical AD (pAD) + mild cognitive impairment (MCI) without SCeVD (pAD/MCI without SCeVD, n = 22), and pAD/MCI with SCeVD (n = 16) for ELISA quantification of cargo proteins. Exosome marker CD81-normalized EDE levels of the cerebrovascular-selective biomarkers large neutral amino acid transporter 1 (LAT-1), glucose transporter type 1 (Glut-1), and permeability-glycoprotein (p-GP, ABCB1) were similarly significantly higher in the CN with SCeVD and pAD/MCI with SCeVD groups than their corresponding control groups without SCeVD. CD81-normalized EDE levels of Aβ40 and Aβ42 were significantly higher in the pAD/MCI with SCeVD group but not in the CN with SCeVD group relative to controls without SCeVD. Levels of normal cellular prion protein (PrPc), a receptor for amyloid peptides, and phospho-181T-tau were higher in both CN and pAD/MCI with SCeVD groups than in the corresponding controls. High EDE levels of Aβ40, Aβ42, and phospho-181T-tau in patients with WMH suggesting SCeVD appear at the pre-clinical or MCI stage of AD and therapeutic lowering of neurotoxic peptide levels may delay progression of AD angiopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.